HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...
There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field studyExpect to ...
Lenacapavir, a twice-yearly injectable, offers a new HIV prevention method, improving adherence compared to more frequent regimens. Phase 3 trials showed lenacapavir's high efficacy in preventing HIV, ...
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Pharmacy students in the U.S. show limited knowledge of HIV prophylaxis, especially PEP, due to inadequate assessment tools. Pharmacists are pivotal in HIV prevention, but their knowledge of PrEP and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback